The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).
 
Apurva Jain
No Relationships to Disclose
 
Rachna T. Shroff
Stock and Other Ownership Interests - Celgene
Consulting or Advisory Role - Agios; Amgen; Celgene; Clovis Oncology; Codiak Biosciences
Research Funding - Agios; Celgene; Lilly
Travel, Accommodations, Expenses - Amgen; Celgene; Codiak Biosciences
 
Mingxin Zuo
No Relationships to Disclose
 
Jacqueline Weatherly
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Randi Isaacs
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Siraj Mahamed Ali
No Relationships to Disclose
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Glenmark; Lilly; Merrimack; NCCN; Regeneron; Research to Practice; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Expert Testimony - Helsinn Therapeutics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen
 
Milind M. Javle
No Relationships to Disclose